Summit Therapeutics (SMMT) Accumulated Depreciation & Amortization (2019 - 2024)
Summit Therapeutics (SMMT) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $1.1 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Accumulated Depreciation & Amortization rose 7.29% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Dec 2024, up 7.29%, and an annual FY2024 reading of $1.1 million, up 7.29% over the prior year.
- Accumulated Depreciation & Amortization was $1.1 million for Q4 2024 at Summit Therapeutics, up from $1.0 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $1.3 million in Q4 2022 and bottomed at $1.0 million in Q4 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
- The sharpest move saw Accumulated Depreciation & Amortization rose 25.19% in 2022, then decreased 19.66% in 2023.
- Year by year, Accumulated Depreciation & Amortization stood at $1.1 million in 2020, then fell by 8.24% to $1.0 million in 2021, then increased by 25.19% to $1.3 million in 2022, then fell by 19.66% to $1.0 million in 2023, then rose by 7.29% to $1.1 million in 2024.
- Business Quant data shows Accumulated Depreciation & Amortization for SMMT at $1.1 million in Q4 2024, $1.0 million in Q4 2023, and $1.3 million in Q4 2022.